Yan Li

6PUBLICATIONS
3CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsEpidemiological methodsMedical infection agents (incl. prions)Traditional Chinese medicine and treatments
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 07, 2026
Efficacy and safety of first-line immune checkpoint inhibitors combinations for extensive-stage small-cell lung cancer: A systematic review and network meta-analysis.

|Jul 29, 2026
The Real-World Safety Profile of Immune Checkpoint Inhibitors in Melanoma: FAERS Pharmacovigilance Analysis Complemented by Randomized Trial Evidence.

|Apr 19, 2024
Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer.

Mingyu Meng, Xiaoxia Liu, Xueyan Liang

|Jul 26, 2023
Cost-effectiveness of camrelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer.

Xueyan Liang, Xiaoyu Chen, Huijuan Li

|Aug 31, 2022
Efficacy and safety of optional parenteral antimicrobial therapy for complicated skin and soft tissue infections: A systematic review and Bayesian network meta-analysis.

Huijuan Li, Xueyan Liang, Guangyan Mo

|Sep 13, 2021
Clinical efficacy and safety of Huachansu injection combination with platinum-based chemotherapy for advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials.

Xinmei Tan, Xueyan Liang, Jiaxi Xi

Pageof 1

Frequent Collaborators

1 joint publications

Xueyan Liang

1 joint publications

Xiaoyu Chen

1 joint publications

Huijuan Li